4 Human Rights, Global Justice, and Disaggregated States: John Rawls, Onora O'Neill, and Anne-Marie Slaughter

A bstract .   Human rights are urgently important rights that all individual persons may validly claim and that all governments are obligated to respect. According to some philosophers, no government can plausibly claim legitimate authority unless its legal and political system ascribes such rights, and no society can plausibly claim to be just unless it has a legitimate government. John Rawls presents his own version of this conception in the context of his account of the moral basis of a just global system of public law, which he calls the Law of Peoples. According to some of his critics, including Onora O'Neill, not only is the Law of Peoples statist, but also it relies on a false view of the state. O'Neill has developed a new conception of an ideally just global order in which states have fewer, and corporations more, powers and obligations to secure human rights, in contrast to Rawls's conception. Her conception is consistent with Anne-Marie Slaughter's account of the transformation of state sovereignty due to globalization. However, contrary to initial appearances, it is not the case that O'Neill's and Slaughter's views taken together require significant modification of Rawls's conception of human rights. There is no fundamental conflict between Rawls's conception of human rights and Slaughter's account of state transformation. And O'Neill's criticisms of Rawls's view are unwarranted.     

From Invention to Innovation: Toward Developing an Integrated Innovation Model for Biotech Firms*

A review of extant literature reveals various theories on innovation, including technology push, market pull, and an organizational approach. All of these theories have been criticized for their lack of integration and inapplicability to today's competitive environment. An integrated view of innovation has emerged that synthesizes the variables in previous approaches. However, the application of this view has been restricted to investigating the innovation processes within the computer and manufacturing industries, whereas the biotechnology industry has been ignored. This is despite biotech managers' well‐acknowledged thirst for innovation and the ability of biotech to shape the way we live. The present article contributes to the literature by applying an integrated approach to the biotech industry, thereby extending understanding of innovation management beyond the traditional field of inquiry. An integrated approach is of particular relevance to biotech companies, given the complexities of managing the industry's long development cycle and intense collaborative activities. In‐depth interviews with eight organizations in Maryland formed the basis for an investigation into the challenges of managing the innovation process in biotechnology firms. The findings revealed that biotech entrepreneurs are ill prepared to lead their organizations through several transformations necessary along the product life cycle because of their fixation on a technology‐push approach and lack of an understanding of integrated innovation. These leaders also lack the commercialization knowledge necessary to push products to markets, resulting in avoidable delays and loss of productivity. The existing research has dispelled myths associated with biotech. Specifically, it suggests biotech entrepreneurs cannot rely solely on inventions but must invest in a timely application of knowledge to organizational and market forces to take full advantage of the innovation potential associated with the industry. This article presents a conceptual framework for applying the integrated innovation model to biotech firms and makes the case for incorporating market‐oriented mechanisms, building and using appropriate organizational capabilities, developing effective collaborations, and creating parallel interactions as major elements in a general strategy toward the success and improved efficiency of biotech companies. The limitations of current research are discussed, and avenues are highlighted for much‐needed future research into the biotech industry.     

Country size,trade concentration and trade instability: An alternative approach

Zusammenfassung Landesgr?βe, Handelskonzentration und Handelsinstabilit?t: Ein alternativer Ansatz. — Die Verwendung einer modifizierten Version des Gini-Hirschman Konzentrationsindex zeigt in Verbindung mit der geographischen und produktm?βigen Verteilung, daβ die Entwicklungsl?nder als Lieferanten ihrer wesentlichen Exporte eine bedeutendere Rolle spielen als früher angenommen wurde, wenn man haupts?chlich die Gr?βe bestimmter Exporte als Anteile der Gesamtk?ufe der Importl?nder dieser Güter betrachtet. Diese Bedeutung eines Landes als Lieferant von Gütern für seine wichtigsten Handelspartner bringt nicht unbedingt mit sich, daβ es sehr empfindlich gegenüber Exporterl?sschwankungen ist, selbst wenn es — gemessen durch den einfachen Gini-Hirschman-Konzentrationskoeffizienten — relativ hohe produktm?βige und geographische Konzentrationsindizes aufweist. Dieser Aufsatz untersucht auβerdem die Landesgr?βe in Relation zum kombinierten Handelsindex sowie zum Index der Handelsinstabilit?t, der nach der Coppockschen Log-Varianz-Methode ermittelt wird. Der in der Literatur über Handelskonzentration im allgemeinen vernachl?ssigte Importsektor wird ebenfalls im Lichte der genannten Analyse untersucht.

---

Résumeé La dimension de pays, la concentration de commerce extérieur et l’instabilité de commerce extérieur: Une approche alternative. — En appliquant une version modifiée des Gini-Hirschman indice de concentration combinant la distribution géographique et de marchandises nous démonstrons que les pays développants sont des offrants plus importants de leurs exportations majeures qu’on croyait auparavant si on considère primairement le volume des exportations spécifiques comme rapport des achats totaux de ces produits spécifiques par les pays importants. La dimension de l’importance d’un pays comme offrant des produits vis-à-vis ses partenaires commerciaux majeurs ne veut pas dire nécessairement qu’il sera fortement sujet à des fluctuations des revenus exportatrices même s’il aurait des indices de concentration géographiques et de marchandises relativement hauts comme mesurés par le simple coéfficient de concentration de Gini-Hirschman. Cet article examine aussi la dimension de pays en relation avec l’indice combiné de commerce et subséquentement avec l’indice d’instabilité de commerce extérieur qui est computé en appliquant la méthode de log-variance de Coppock. Nous analysons aussi le secteur d’importation, qui est généralement ignoré dans la littérature sur la concentration commerciale en jour de l’analyse susdite.

---

Resumen Tama?o de un país, concentración del comercio e inestabilidad comercial: una aproximación alternativa. — La utilización de una versión modificada del índice de concentración Gini/Hirschman, en que se combina la distribución geográfica y de productos, muestra que los países en desarrollo son oferentes más importantes de sus principales exportaciones de lo que previamente se creía, si se observa primeramente el tama?o de exportaciones específicas como participación en las compras de estos productos especificos por parte de los países importadores. La magnitud de la importancia de un país como oferente de productos para sus principaìes países compradores no significa necesariamente, que será altamente susceptible a fluctuaciones en los ingresos de exportación, a pesar de que puede tener índices de concentración geográfica y de productos relativamente altos, medidos por medio del indice de concentración simple de Gini/Hirschman. Este estudio también examina el tama?o de países en relación con el íncice de comercio combinado y, a la vez, con el indice de inestabilidad comercial que es computado por medio del método de varianza logarítmica de Coppock. El sector de importaciones, que generalmente ha sido ignorado en la literatura de concentración, también es analizado a la luz del presente análisis.

     

Abwege des Verbraucherschutzes im Versicherungsrecht-Stellungnahme zu Hellners Beitrag in ZVP, 4, 1980/4

Ohne Zusammenfassung     

Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding,urgent surgery,or procedural interventions: interim results from the RE-VERSE AD™ study

Aims: Patients treated with anticoagulants may experience serious bleeding or require urgent surgery or intervention, and may benefit from rapid anticoagulant reversal. This exploratory analysis assessed healthcare resource utilization (HCRU) in patients treated with idarucizumab, a specific reversal agent for dabigatran etexilate.

Materials and methods: RE-VERSE AD? (NCT02104947), a prospective, multi-center open-label study, is evaluating idarucizumab for dabigatran reversal in patients with serious bleeding (Group A) or undergoing emergency surgery/procedures (Group B). HCRU outcome measures evaluated in the first 90 patients enrolled were use of blood products and pro-hemostatic agents, length of stay (LOS) in hospital, and LOS in intensive care unit (ICU).

Results: Blood products or pro-hemostatic agents were given to 63% (32/51) of patients in Group A and 23% (9/39) of patients in Group B on the day of/day after surgery. An overnight hospital stay was reported for 82% (42/51) of patients in Group A with median LOS?=?7 (range?=?1–71) bed-days. For Group B, 92% (36/39) had an overnight hospital stay with a median LOS?=?9 (range?=?1–92) bed-days. In Group A, 17 patients were admitted to the ICU for at least 1?day with median LOS?=?4 (range?=?1–44) days; in Group B the number was 15 with median LOS?=?2 (range?=?1–92) days.

Limitations: The lack of a control group and the small patient numbers limit the strength of the conclusions.

Conclusions: The use of idarucizumab may simplify emergency management of dabigatran-treated patients with life-threatening bleeds and reduce perioperative complications in patients undergoing emergency surgery.